UGDP Trial

Curtis L. Meinert

doi:10.1002/9781118596005.ch76

UGDP Trial

Curtis L. Meinert

Bloomberg School of Public Health

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The University Group Diabetes Program (UGDP) was a multicenter, investigatorinitiated, trial started in 1960 and finished two decades later designed to assess the value of established antihyperglycemic drugs for prevention of the late complications of adult-onset diabetes. The trial has historical importance in that it was one of the first multicenter long-term prevention trials designed to assess the safety and efficacy of established treatments. This chapter provides a chronology of the trial and account of the legal battle mounted by the Committee for the Care of the Diabetic (CCD) to forestall the label change proposed by the FDA regarding the possibility of cardiovascular (CV) risks associated with tolbutamide. It also provides a list of criticisms leveled against the trial and responses to those criticisms.

Original language	English (US)
Title of host publication	Concepts, Principles, Trials, and Designs
Publisher	wiley
Pages	894-917
Number of pages	24
Volume	1
ISBN (Electronic)	9781118596005
ISBN (Print)	9781118595923
DOIs	https://doi.org/10.1002/9781118596005.ch76
State	Published - Sep 26 2014

Keywords

Cardiovascular (CV) risks
University Group Diabetes Program (UGDP)

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781118596005.ch76

Cite this

@inbook{93b70ffa9ce04f23a4df323ba23ae78b,

title = "UGDP Trial",

abstract = "The University Group Diabetes Program (UGDP) was a multicenter, investigatorinitiated, trial started in 1960 and finished two decades later designed to assess the value of established antihyperglycemic drugs for prevention of the late complications of adult-onset diabetes. The trial has historical importance in that it was one of the first multicenter long-term prevention trials designed to assess the safety and efficacy of established treatments. This chapter provides a chronology of the trial and account of the legal battle mounted by the Committee for the Care of the Diabetic (CCD) to forestall the label change proposed by the FDA regarding the possibility of cardiovascular (CV) risks associated with tolbutamide. It also provides a list of criticisms leveled against the trial and responses to those criticisms.",

keywords = "Cardiovascular (CV) risks, University Group Diabetes Program (UGDP)",

author = "Meinert, {Curtis L.}",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley & Sons, Inc.",

year = "2014",

month = sep,

day = "26",

doi = "10.1002/9781118596005.ch76",

language = "English (US)",

isbn = "9781118595923",

volume = "1",

pages = "894--917",

booktitle = "Concepts, Principles, Trials, and Designs",

publisher = "wiley",

}

TY - CHAP

T1 - UGDP Trial

AU - Meinert, Curtis L.

PY - 2014/9/26

Y1 - 2014/9/26

N2 - The University Group Diabetes Program (UGDP) was a multicenter, investigatorinitiated, trial started in 1960 and finished two decades later designed to assess the value of established antihyperglycemic drugs for prevention of the late complications of adult-onset diabetes. The trial has historical importance in that it was one of the first multicenter long-term prevention trials designed to assess the safety and efficacy of established treatments. This chapter provides a chronology of the trial and account of the legal battle mounted by the Committee for the Care of the Diabetic (CCD) to forestall the label change proposed by the FDA regarding the possibility of cardiovascular (CV) risks associated with tolbutamide. It also provides a list of criticisms leveled against the trial and responses to those criticisms.

AB - The University Group Diabetes Program (UGDP) was a multicenter, investigatorinitiated, trial started in 1960 and finished two decades later designed to assess the value of established antihyperglycemic drugs for prevention of the late complications of adult-onset diabetes. The trial has historical importance in that it was one of the first multicenter long-term prevention trials designed to assess the safety and efficacy of established treatments. This chapter provides a chronology of the trial and account of the legal battle mounted by the Committee for the Care of the Diabetic (CCD) to forestall the label change proposed by the FDA regarding the possibility of cardiovascular (CV) risks associated with tolbutamide. It also provides a list of criticisms leveled against the trial and responses to those criticisms.

KW - Cardiovascular (CV) risks

KW - University Group Diabetes Program (UGDP)

UR - http://www.scopus.com/inward/record.url?scp=85018065049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018065049&partnerID=8YFLogxK

U2 - 10.1002/9781118596005.ch76

DO - 10.1002/9781118596005.ch76

M3 - Chapter

AN - SCOPUS:85018065049

SN - 9781118595923

VL - 1

SP - 894

EP - 917

BT - Concepts, Principles, Trials, and Designs

PB - wiley

ER -

UGDP Trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this